Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

HEHany ElmariahNTNancy Torres

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows hypomethylating agent maintenance improves overall survival in TP53 mutant acute myeloid leukemia patients.

Key Points

  • Overall survival improved to 32 months with HMA maintenance versus 10 months without.
  • Twenty-nine percent of TP53 mutant AML patients received HMA maintenance, showing significant survival benefits.
  • Retrospective cohort analysis identified key predictors like baseline TP53 variant allele frequency and cytogenetic status.
  • Findings suggest the need for pivotal studies in molecular subgroups utilizing HMA maintenance therapy.

Cite This Study

Elmariah et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d60chttps://doi.org/10.1182/blood-2025-4291
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT2025 · 1 citations
  2. 2Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis2025
  3. 3Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database2025
  4. 4Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes2025
  5. 5Acute Myeloid Leukemia (AML) with TP53 alteration and outcomes after allogeneic hematopoietic stem cell transplantation: A CIBMTR registry study2025 · 1 citations